Phase 2 N=9 A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
Primary Focal Segmental Glomerulosclerosis
Primary: Changes in Proteinuria (With Stable Renal Function) — 7.6; 7.27 g/day — p=0.49
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=662 Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris
Acne Vulgaris
Primary: Change From Baseline in Inflammatory Lesion Counts to Week 16 (Last Observation Carried Forward [LOCF]) — -16.1; -12.9; -12.6 lesion count — p=0.006
Phase 2 N=385 Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population
Influenza · Influenza Vaccines
Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer
Phase 2 N=13 DAW1033B2 in Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA)
Primary: Apnea Hypopnea Index (AHI, Events/Hour of Sleep) — 33; 20.4 events/hour of sleep — p=0.47
Phase 2 N=343 Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention
Chronic Migraine or Episodic Migraine
Primary: Change From Baseline in Monthly Migraine Days to the Last 4 Weeks of the 12 Week Double-Blind Treatment Period — -2.45; -2.20; -2.19 days — p=0.66
Phase 2 N=223 Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: Percentage of Participants With Stringent Complete Response (sCR) — 32.0; 42.4 Percentage of participants
Phase 2 N=12 Effects of High Dose Calcitriol in Breast Cancer Patients
Breast Cancer
Primary: Mean Change in Bone Resorption: NTX (N-terminal Telopeptide) — NA nmol
Phase 2 N=460 A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults
Obesity · Overweight
Primary: Percent Change From Baseline in Body Weight at 24 Weeks — -1.24; -2.04; -3.52; -4.37 Percent change — p=<0.0001
Phase 2 N=22 A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Number of Subjects withTreatment-Emergent Adverse Events (Safety and Tolerability) — 7 Participants
Phase 2 N=9 A Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization
Antibiotic Resistant Strain
Primary: Percentage of Participants With VRE Decolonization — 1; 1 Participants
Phase 2 N=21 A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Cardiomyopathy, Hypertrophic Obstructive · Left Ventricular Outflow Tract Obstruction
Primary: Change in Post-exercise Peak LVOT Gradient From Baseline to Week 12 — -89.5; -25.0 mm Hg
Phase 2 N=133 Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Metastatic Colorectal Carcinoma · Recurrent Colorectal Carcinoma · Refractory Colorectal Carcinoma
Primary: Progression Free Survival (PFS) — 4.37; 3.32 months — p=0.051
Phase 2 N=11 Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function
Chronic Kidney Disease (CKD)
Primary: Number of Patients With Reported Adverse Events Receiving Escalating Doses of LHW090 (Part 1) — 1; 0; 1; 2 Count of Participants
Phase 2 N=11 DAW1033D in Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA)
Primary: Apnea Hypopnea Index (AHI, Events/Hour of Sleep) — 21.6; 37.9 events/hour of sleep — p=0.56
Phase 2 N=81 Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL
Diffuse Large B-cell Lymphoma
Primary: Number of Participants With Best Objective Response Rate (ORR) — 46; 46 Participants